Literature DB >> 3040235

Changing incidence of hepatocellular carcinoma in Japan.

K Okuda, I Fujimoto, A Hanai, Y Urano.   

Abstract

A trend in the incidence of hepatocellular carcinoma (HCC) in Japan was studied from the data of the Osaka Cancer Registry (population, 8,512,351 in 1981) for the period of 1963-1983, the Vital Statistics of Japan, Ministry of Health and Welfare, and the Japan Autopsy Registry which contained 594,132 individually filed cases in the 26-year period from 1958 to 1983. Both cancer registry data and autopsy records showed a more than 2-fold increase in HCC incidence, particularly in the last 10 years or so, among males and a less pronounced increase in females. The same trend was borne out by the cancer registries of Nagasaki City and Miyagi Prefecture and the Vital Statistics. When studied with the autopsy data, it was found that the numbers of autopsies for cirrhosis without HCC and autopsies for HCC (with and without cirrhosis) were about the same in 1958-1961 and that currently (1980-1983) the latter is about 2 times the former. As one of the possible causes of increase in HCC incidence other than prolonged survival of patients with cirrhosis, chronic non-A, non-B hepatitis is discussed.

Entities:  

Mesh:

Year:  1987        PMID: 3040235

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  46 in total

1.  Interferon inhibits progression of liver fibrosis and reduces the risk of hepatocarcinogenesis in patients with chronic hepatitis C: a retrospective multicenter analysis of 652 patients.

Authors:  Mitsuhiro Takimoto; Shogo Ohkoshi; Takafumi Ichida; Yasuo Takeda; Minoru Nomoto; Hitoshi Asakura; Akira Naito; Shigeki Mori; Kojiro Hata; Kentaro Igarashi; Hidenori Hara; Hironobu Ohta; Kenji Soga; Toshiaki Watanabe; Tomoteru Kamimura
Journal:  Dig Dis Sci       Date:  2002-01       Impact factor: 3.199

Review 2.  Clinical aspects and epidemiology of hepatitis B and C viruses in hepatocellular carcinoma in Japan.

Authors:  K Kiyosawa; S Furuta
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

3.  Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults.

Authors:  S D Ryder
Journal:  Gut       Date:  2003-05       Impact factor: 23.059

Review 4.  Glycosylation and liver cancer.

Authors:  Anand Mehta; Harmin Herrera; Timothy Block
Journal:  Adv Cancer Res       Date:  2015-02-07       Impact factor: 6.242

Review 5.  Nutritional model of hepatocarcinogenesis. Rats fed choline-devoid diet.

Authors:  B Lombardi; N Chandar; J Locker
Journal:  Dig Dis Sci       Date:  1991-07       Impact factor: 3.199

6.  R-Etodolac decreases beta-catenin levels along with survival and proliferation of hepatoma cells.

Authors:  Jaideep Behari; Gang Zeng; Wade Otruba; Michael D Thompson; Peggy Muller; Amanda Micsenyi; Sandeep S Sekhon; Lorenzo Leoni; Satdarshan P S Monga
Journal:  J Hepatol       Date:  2006-12-21       Impact factor: 25.083

7.  Evaluation of hepatocellular carcinoma with portal vein tumor thrombosis by CEUS before and after hepatic arterial infusion chemotherapy.

Authors:  Hiroyuki Kirikoshi; Satoru Saito; Norio Ueno; Kaori Suzuki; Hirokazu Takahashi; Masato Yoneda; Koji Fujita; Atsushi Nakajima
Journal:  J Med Ultrason (2001)       Date:  2010-04-10       Impact factor: 1.314

8.  Primary biliary cirrhosis associated with cholangiocarcinoma.

Authors:  N Akisawa; T Maeda; K Tsuda; I Nishimori; M Morita; S Iwasaki; A Tomita; T Saibara; S Onishi; Y Kiyoku; H Enzan
Journal:  Dig Dis Sci       Date:  1998-09       Impact factor: 3.199

Review 9.  Geographic heterogeneity of hepatocellular carcinoma.

Authors:  K Okuda
Journal:  Gastroenterol Jpn       Date:  1990-12

10.  Weak association between SEN virus viremia and liver disease.

Authors:  Hideo Yoshida; Naoya Kato; Yasushi Shiratori; Runxuan Shao; Yue Wang; Shuichiro Shiina; Masao Omata
Journal:  J Clin Microbiol       Date:  2002-09       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.